Literature DB >> 23826438

Improvement in Visual Symptomatology after Endovascular Treatment of Cavernous Carotid Aneurysms: A Multicenter Study.

Doniel Drazin1, Armen Choulakian, Miriam Nuño, Ravi Gandhi, Randall C Edgell, Michael J Alexander.   

Abstract

INTRODUCTION: Aneurysms arising from the cavernous internal carotid artery (CCAs) pose technical challenges for surgical management and such patients are frequently referred for endovascular treatment. These aneurysms often produce a variety of neurological deficits, primarily those related to oculoparesis. Our purpose was to determine the visual and neurological outcome of patients with treated CCAs.
METHODS: We reviewed the medical records and angiograms for patients who underwent endovascular treatment for CCAs at three academic medical centers. The following outcomes were analyzed: angiographic assessment, visual improvement and outcome at 3 months using Glasgow Outcome Scale (GOS).
RESULTS: Thirty-four patients (mean age 54.7 years) were treated for CCAs. The mean aneurysm size was 14.2 mm (range: 3-45 mm), and fourteen patients (41.2%) required stent assistance. Twenty-one aneurysms (61.8%) were completely occluded; nine aneurysms (26.6%) had near-complete occlusion; 4 aneurysms (11.8%) had partial occlusion. Seven patients (20.6%) required retreatment. Fifteen of the 34 patients (44.1%) presented with visual symptoms, while only eight patients had residual visual symptomatology at follow-up (44.1% vs. 23.5%; p=0.02). Patients that presented with visual symptoms (N=15) had a mean aneurysm size of 24.5 mm, while those without visual symptoms (N=19) had a size of 7.5 mm (p=0.001). Follow-up GOS was good (4-5) in 29 patients (90.6%). No thromboembolic complications were observed. One patient died (3.1%) of an unrelated cause.
CONCLUSIONS: Most patients in this multicenter series improved or remained stable after treatment. The results of this study indicate that endovascular treatment may improve the outcome of visual symptoms in patients with large cavernous aneurysms with low periprocedural morbidity. COMPETING INTERESTS: MJA is a consultant for Stryker and Codman. AC receives a Cordis Endovascular Fellowship Training Grant and a Stryker Endovascular Neurosurgery Post-graduate Fellow Grant. JUSTIFICATION OF AUTHORSHIP: Dr. Drazin: Conception and Design, Drafting the Article and Critically Revising the Article Dr. Choulakian: Analysis and Interpretation of Data and Drafting the Article Dr. Nuno: Analysis and Interpretation of Data Dr. Gandhi: Analysis and Interpretation of Data and Drafting the Article Dr. Edgell: Analysis and Interpretation of Data and Drafting the Article Dr. Alexander: Critically Revising the Article and Conception and Design.

Entities:  

Keywords:  Cavernous Carotid Aneurysm (CCA); Endovascular treatment; Glasgow Outcome Scale (GOS); Raymond Royd (RR) Grade; Visual Sympathology

Year:  2013        PMID: 23826438      PMCID: PMC3693997     

Source DB:  PubMed          Journal:  J Vasc Interv Neurol        ISSN: 1941-5893


  10 in total

1.  Treatment strategy for giant aneurysms in the cavernous portion of the internal carotid artery.

Authors:  Yutaka Kai; Jun-ichiro Hamada; Motohiro Morioka; Shigetoshi Yano; Takamasa Mizuno; Jun-ichiro Kuroda; Tatemi Todaka; Hideo Takeshima; Jun-ichi Kuratsu
Journal:  Surg Neurol       Date:  2006-10-06

Review 2.  Presentation, natural history, and management of carotid cavernous aneurysms.

Authors:  Hadas Stiebel-Kalish; Yuval Kalish; Ruth Huna Bar-On; Avi Setton; Yasu Niimi; Alejandro Berenstein; Mark J Kupersmith
Journal:  Neurosurgery       Date:  2005-11       Impact factor: 4.654

Review 3.  Giant cavernous carotid aneurysms: clinical presentation in fifty-seven cases.

Authors:  C D Hahn; D A Nicolle; S P Lownie; C G Drake
Journal:  J Neuroophthalmol       Date:  2000-12       Impact factor: 3.042

4.  Cavernous internal carotid artery aneurysms treated with electrolytically detachable coils.

Authors:  V V Halbach; R T Higashida; C F Dowd; R W Urwin; P A Balousek; T E Lempert; G B Hieshima
Journal:  J Neuroophthalmol       Date:  1997-12       Impact factor: 3.042

5.  Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment.

Authors:  David O Wiebers; J P Whisnant; J Huston; I Meissner; R D Brown; D G Piepgras; G S Forbes; K Thielen; D Nichols; W M O'Fallon; J Peacock; L Jaeger; N F Kassell; G L Kongable-Beckman; J C Torner
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

6.  Aneurysms of the intracavernous carotid artery: natural history and indications for treatment.

Authors:  M E Linskey; L N Sekhar; W L Hirsch; H Yonas; J A Horton
Journal:  Neurosurgery       Date:  1990-06       Impact factor: 4.654

7.  Long term visual and neurological prognosis in patients with treated and untreated cavernous sinus aneurysms.

Authors:  N Goldenberg-Cohen; C Curry; N R Miller; R J Tamargo; K P J Murphy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 8.  Cavernous carotid aneurysms: to treat or not to treat?

Authors:  Christopher S Eddleman; Michael C Hurley; Bernard R Bendok; H Hunt Batjer
Journal:  Neurosurg Focus       Date:  2009-05       Impact factor: 4.047

9.  Presentation and treatment of carotid cavernous aneurysms.

Authors:  Lucas Perez de Vasconcellos; Juan Antônio Castro Flores; José Carlos Esteves Veiga; Mário Luiz Marques Conti; Pedro Shiozawa
Journal:  Arq Neuropsiquiatr       Date:  2008-06       Impact factor: 1.420

10.  Symptomatic cavernous sinus aneurysms: management and outcome after carotid occlusion and selective cerebral revascularization.

Authors:  Melvin Field; Charles A Jungreis; Nicole Chengelis; Holly Kromer; Lori Kirby; Howard Yonas
Journal:  AJNR Am J Neuroradiol       Date:  2003 Jun-Jul       Impact factor: 3.825

  10 in total
  1 in total

1.  Anterior Optic Pathway Compression Due to Internal Carotid Artery Aneurysms: Neurosurgical Management and Outcomes.

Authors:  Wonhyoung Park; Jung Cheol Park; Kyunghwa Han; Jae Sung Ahn; Byung Duk Kwun
Journal:  J Stroke       Date:  2015-09-30       Impact factor: 6.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.